Health Canada has recently granted approval for a new treatment aimed at alleviating moderate to severe hot flashes and night sweats in women grappling with breast cancer. The drug, Elinzanetant—marketed under the brand name Lynkuet—was initially authorised in July 2025 for menopausal symptoms but has now been validated for use among breast cancer patients following a comprehensive study. This new market authorisation came into effect on Friday, signalling a significant advancement in supportive care for this vulnerable group.
Elinzanetant: A Groundbreaking Treatment
Elinzanetant, developed by Bayer, stands out as a non-hormonal therapy that precisely targets hyperactive neurons, which often become overstimulated in the absence of estrogen. This is particularly relevant for breast cancer patients, as approximately two-thirds of breast cancers are hormone-receptor positive and necessitate the suppression of estrogen for effective treatment. Consequently, oncologists frequently employ anti-estrogen therapies that can trigger distressing vasomotor symptoms, including hot flashes and night sweats.
Dr. Christine Brezden-Masley, medical director of the cancer programme at Sinai Health in Toronto, highlighted the limited options available to breast cancer patients for managing these symptoms. Unlike other women experiencing menopause, those undergoing treatment for breast cancer are typically unable to utilise hormone replacement therapy. “The clinical trial with Elinzanetant was the very first one that actually looked at breast cancer patients on anti-estrogen therapy,” Dr. Brezden-Masley remarked, noting that many women endure these symptoms for five to ten years while on endocrine therapy.
Clinical Study and Results
The effectiveness of Elinzanetant was demonstrated in the OASIS-4 study, a Phase 3 randomised, placebo-controlled trial involving 395 women aged between 18 and 70. Participants, all undergoing endocrine therapy for breast cancer, were required to experience a minimum of 35 moderate to severe hot flashes or night sweats each week. Over the course of 52 weeks, the study revealed that those taking Elinzanetant experienced a marked reduction in both the frequency and severity of their symptoms, as well as improved sleep quality. Notably, 91.6% of participants opted to continue the treatment for an additional two years following the trial.
Dr. Dave Cescon, an oncologist at the Princess Margaret Cancer Centre, emphasised the historical neglect of menopausal symptoms in breast cancer treatment. He expressed optimism about the approval of Elinzanetant as a significant advancement in patient care, acknowledging its potential to greatly improve daily functioning and overall quality of life for many women.
Personal Impact: Real Stories from Patients
The effects of hot flashes can be debilitating, as experienced by Laurie Legere, a 47-year-old hospital administrator from Toronto. Following her breast cancer diagnosis, she began chemotherapy, which triggered disruptive hot flashes that severely impacted her daily activities and sleep. “I would just start getting hot flashes in the middle of meetings or the middle of presentations,” Legere shared. Despite exploring various treatment options, including gabapentin, she struggled to find effective relief without intolerable side effects.
With the recent approval of Elinzanetant, Legere is hopeful for a better quality of life. “I’m looking forward to hopefully having a much better experience,” she stated, underscoring the critical need for effective symptom management in this patient population.
Future Considerations and Availability
While the approval of Elinzanetant marks a significant milestone, it is important to note that the drug is not yet publicly funded in Canada, and Bayer has not disclosed its pricing details. This raises concerns about accessibility for patients who may benefit from the treatment but face financial barriers.
Why it Matters
The introduction of Elinzanetant as a treatment option for hot flashes and night sweats in breast cancer patients represents a pivotal moment in women’s health. By addressing a common yet often overlooked issue, this new therapy has the potential to significantly enhance the quality of life for those undergoing cancer treatment. As health systems strive to provide comprehensive care, it is crucial that policymakers consider equitable access to such advancements, ensuring that all patients can benefit from emerging therapies.
